Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

[Cover]

[Document Submitted] Extraordinary Report

[Submitted to] Director, Kanto Local Finance Bureau

[Date of Submission] June 24, 2022

[Company Name] Ono Yakuhin Kogyo Kabushiki-Kaisha

[Company Name (in English)] ONO PHARMACEUTICAL CO., LTD.

[Position and Name of Representative] Gyo Sagara, President, Representative Director, and Chief

**Executive Officer** 

[Location of Head Office] 1-5, Doshomachi 2-chome, Chuo-ku, Osaka, Japan

(The above is the location of the registered head office. The actual head office operations are located at 8-2, Kyutaromachi 1-chome,

Chuo-ku, Osaka, Japan.)

[Phone No.] Not applicable

[Contact for Communications] Not applicable

[Nearest Contact] 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, Japan

Phone No. +81-(0)6-6263-5670

[Contact for Communications] Kazuhiro Nagahama, Senior Director, Finance & Accounting

[Place Where Available for Public Tokyo Stock Exchange, Inc.

Inspection (2-1 Nihombashi Kabutocho, Chuo-ku, Tokyo, Japan)

#### 1 [Reason for Filing]

As the following proposals were resolved at the 74th Ordinary General Shareholders' Meeting of Ono Pharmaceutical Co., Ltd. (the "Company") held on June 23, 2022, the Company hereby files this Extraordinary Report pursuant to the provisions of Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and the provisions of Article 19, Paragraph 2, Item 9-2 of the Cabinet Office Ordinance on the Disclosure of Corporate Affairs, etc.

# 2 [Description of Report]

(1) Date of the Ordinary General Shareholders' Meeting June 23, 2022

## (2) Details of Proposals Resolved

# Proposal 1 Appropriation of Surplus

Year-End Dividend

- 1 Type of dividend property

  Cash
- (2) Allocation of dividend property to shareholders and total amount of such allocation ¥28 per share of common stock

  Total dividend amount: ¥13,672,671,264
- (3) Effective date of the distribution of the dividend June 24, 2022

## Proposal 2 Partial Amendments to the Articles of Incorporation

- ① To give flexibility to the operation of the general shareholders' meeting, the provisions of the convener and chairperson of the general shareholders' meeting were changed.
- ② Necessary changes were made to the Articles of Incorporation in order to prepare for the introduction of the system for providing reference materials for the general shareholders' meeting in electronic format, in conjunction with the enforcement of the revised provisions stipulated in the supplementary provision of Article 1 of the Act Partially Amending the Companies Act (Act No. 70 of 2019) on September 1, 2022.

### Proposal 3 Election of Eight (8) Members of the Board of Directors

Eight (8) Members of the Board of Directors, namely, Gyo Sagara, Toshihiro Tsujinaka, Toichi Takino, Isao Ono, Kiyoaki Idemitsu, Masao Nomura, Akiko Okuno and Shusaku Nagae were elected.

#### Proposal 4 Revision to the Amount of Remuneration for Members of the Board of Directors

The maximum amount of monetary remuneration for Members of the Board of Directors was revised to 700 million yen per year (including a maximum of 100 million yen per year for Outside Directors; excluding the amount paid as employee salary).

Proposal 5 Determination of the Amount and Details of the Remuneration for Granting Restricted Stock to Members of the Board of Directors

The maximum amount of remuneration for granting tenure-based restricted stock and performance-linked restricted stock as part of the stock remuneration system for Members of the Board of Directors (excluding Outside Directors; hereinafter the same shall apply) was set at 100 million yen per year for the former and 300 million yen per year for the latter, separately from the amount of remuneration for Members of the Board of Directors determined in Proposal 4.

In conjunction, the maximum amount of remuneration related to stock-based remuneration-type stock options was abolished.

Additionally, the maximum amount of remuneration for allotting restricted stock to Members of the Board of Directors was set at 400 million yen per year for the 75th fiscal year (from April 1, 2022 to March 31, 2023) only, in lieu of the waiver of the unexercised portion of the stock acquisition rights as stock-based remuneration-type stock options already allotted in previous years, separately from the maximum amount of remuneration for Members of the Board of Directors determined in Proposal 4 and the maximum amount of remuneration for the stock remuneration system described above.

(3) The number of voting rights either approving, disapproving or abstaining on proposals resolved; requirements for the approval of the resolutions and their results

Proposal	For (Number of voting rights)	Against (Number of voting rights)	Abstentions (Number of abstentions)	Requirements for approval	Results Approval ratio (%)	
Proposal 1 Appropriation of Surplus	4,332,678	2,338	0	(Note 1)	Approved	99.922
Proposal 2 Partial Amendments to the Articles of Incorporation	4,332,959	2,099	0	(Note 2)	Approved	99.928
Proposal 3 Election of Eight (8) Members of the Board of Directors						
Gyo Sagara	3,996,276	338,540	215	(Note 3)	Approved	92.164
Toshihiro Tsujinaka	4,303,874	31,166	1		Approved	99.257
Toichi Takino	4,315,702	19,338	1		Approved	99.530
Isao Ono	4,281,958	53,081	1		Approved	98.752
Kiyoaki Idemitsu	4,315,687	19,353	1		Approved	99.530
Masao Nomura	4,313,500	21,540	1		Approved	99.479
Akiko Okuno	4,313,871	9,287	11,883		Approved	99.488
Shusaku Nagae	4,313,002	22,038	1		Approved	99.468
Proposal 4 Revision to the Amount of Remuneration for Members of the Board of Directors	4,119,797	213,849	1,404	(Note 1)	Approved	95.012
Proposal 5 Determination of the Amount and Details of the Remuneration for Granting Restricted Stock to Members of the Board of Directors	4,278,346	56,705	0	(Note 1)	Approved	98.669

Notes) 1. Proposal 1, Proposal 4 and Proposal 5 require approval by a majority of voting rights of the shareholders in attendance eligible for exercising voting rights.

- 2. Proposal 2 requires the attendance of shareholders holding one-third or more of voting rights owned by shareholders eligible for exercising voting rights and approval by not less than two-thirds of said voting rights.
- 3. Proposal 3 requires the attendance of shareholders holding one-third or more of voting rights owned by shareholders eligible for exercising voting rights and approval by the majority of said voting rights.

(4) The reason why a portion of the voting rights held by the shareholders in attendance at the Ordinary General Shareholders' Meeting was not counted

Resolutions of all the proposals have been legitimately reached in accordance with the Companies Act, as the requirements for approval have been met based on the number of confirmed votes of approval or disapproval by counting the voting rights exercised up to the day before this General Shareholders' Meeting and those of shareholders in attendance. Therefore, voting rights of the shareholders in attendance which are not confirmed as to whether they are approving, disapproving, or abstaining are not included in the count.